Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA), for GH-secreting pituitary tumors poorly controlled by SSAs alone. No information is available on specific indications for or relative efficacies of PEGV+SSA versus PEGV monotherapy. Aim of our study was to characterize real-life clinical use of PEGV vs. PEGV+SSA for SSA-resistant acromegaly (patient selection, long-term outcomes, adverse event rates, doses required to achieve control).
Bianchi, A., Valentini, F., Iuorio, R., Poggi, M., Baldelli, R., Passeri, M., Giampietro, A., Tartaglione, L., Chiloiro, S., Appetecchia, M., Gargiulo, P., Fabbri, A., Toscano, V., Pontecorvi, A., De Marinis Grasso, L., Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes, <<JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH>>, 2013; 32 (Giugno): 40-40. [doi:10.1186/1756-9966-32-40] [http://hdl.handle.net/10807/53985]
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes
Bianchi, Antonio;Giampietro, Antonella;Tartaglione, Linda;Chiloiro, Sabrina;Pontecorvi, Alfredo;De Marinis Grasso, Laura
2013
Abstract
Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA), for GH-secreting pituitary tumors poorly controlled by SSAs alone. No information is available on specific indications for or relative efficacies of PEGV+SSA versus PEGV monotherapy. Aim of our study was to characterize real-life clinical use of PEGV vs. PEGV+SSA for SSA-resistant acromegaly (patient selection, long-term outcomes, adverse event rates, doses required to achieve control).
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
